Dr Reddy’s Labs to promote, distribute Sanofi paediatric, adult vaccine brands in India

Hyderabad: Dr Reddy’s Laboratories Ltd., a global pharmaceutical
company, has announced that it has entered into an exclusive partnership with Sanofi Healthcare India
Private Limited (“SHIPL”) to promote and distribute their vaccine brands across private markets in
India.

Under the arrangement, Dr. Reddy’s will have exclusive rights to promote and distribute Sanofi’s paediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim,
Menactra, FluQuadri, Adacel and Avaxim 80U.
These brands saw combined sales of approx. Rs 426 crores (approx. USD 51 million) as per IQVIA MAT February 2024. Sanofi will continue to own,
manufacture, and import these brands to the country.
Preeti Futnani, General Manager India for Vaccines, Sanofi, said, “Vaccine confidence has reached
its highest in India in the last few years. Yet, there is much to be done for the rest of the country’s large
unvaccinated cohort. To fulfil our long-term commitment to India and expand our geographic reach, we’re
pleased to partner with Dr. Reddy’s Laboratories (Dr. Reddy’s) for exclusive distribution and promotion.
We’re confident this partnership will further bolster our promise of saving millions of lives against vaccines preventable diseases with improved vaccination coverage.”
M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr.
Reddy’s, said, “We are happy to have the opportunity to leverage our strengths in promotion and
distribution to considerably expand engagement with healthcare professionals and help widen access of
Sanofi’s well-established and trusted vaccine brands in India. We continue our efforts to become the
partner of choice in bringing novel, innovative and trusted drugs to patients in India through strategic
collaborations. The portfolio now gives Dr. Reddy’s a strong presence in the vaccine segment, propelling
us to the second position among vaccines players in India. Through each product and partnership, our
aim is to serve over 1.5 billion patients by 2030.”

About the portfolio: 

Brand

Label Indication

Hexaxim

Indicated for primary and booster vaccination of infants and toddlers
from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B,
poliomyelitis and invasive diseases caused by Haemophilusinfluenzae type b
(Hib).

Pentaxim

Indicated for the active immunization of children against Diphtheria,
Pertussis, Tetanus, Polio and against invasive infections due to
Haemophilusinfluenzae type b bacterium (such as meningitis, septicaemia,
etc.) in children from the age of 2 months or according to local
recommendations. This vaccine does not protect against infections caused by
other types of Haemophilusinfluenzae nor against meningitis due to other
micro-organisms.

Tetraxim

Indicated in the joint prevention of diphtheria, tetanus, pertussis
and poliomyelitis: for primary vaccination in infants from the age of 2
months, for booster vaccination, one year after primary vaccination during
the second year of life, for booster vaccination between 5 and 13 years of
age, according to official recommendations

Menactra

Indicated for active immunization to prevent invasive meningococcal
disease caused by N. meningitidis serogroups A, C, Y, and W-135. MENACTRA® is
approved for use in individuals 9 months through 55 years of age

FluQuadri

FluQuadri is an inactivated quadrivalent influenza vaccine indicated
for the prevention of influenza disease caused by influenza types A and B
viruses contained in the vaccine. FluQuadri® is approved for use in persons 6
months of age and older.

Adacel

Indicated for active booster immunization for the prevention of
tetanus, diphtheria and pertussis (whooping cough) as a single dose in
persons aged 11 to 54 years. In accordance with local recommendations,
ADACEL® may be considered as an alternative for the fifth dose of tetanus,
diphtheria and acellular pertussis vaccine (DTaP) in children 4 to 6 years of
age, concomitantly administered with Inactivated Poliomyelitis Vaccine (IPV),
at separate sites to complete the vaccination series for this age, when indicated

Avaxim 80U

This vaccine is recommended for the prevention of the infection
caused by the Hepatitis A virus in children aged from 12 months to 15 years
inclusive
Read also: Sanofi, Cipla collaborate to expand Central Nervous System portfolio reach in India
Facebook Comments